Study of Renal Toxicity in Wistar Rats Following the Action of Amphotericin B Solution Prepared under Extreme pH Conditions

DOI: 10.4236/fns.2011.27100   PDF   HTML   XML   3,826 Downloads   6,816 Views   Citations


Our study related to the renal toxicity of Wistar rats induced by solutions of amphotericin B prepared under extreme conditions of pH (5.4 and 10.8). The results obtained show that with pH 5.4 of stock solution, urea and creatinin rate blood is not disturbed. These means that the renal function is not deteriorated by the amphotericin B. Furthers, treatment of animals infected by the yeast Candida albicans, with the solution of amphotericin B prepared at pH 5.4 and injected at 0.5 mg of AmB/Kg every 24 hours, seems to be effective.

Share and Cite:

L. Belkherroubi-Sari, Z. Boucherit, K. Boucherit and S. Belbraouet, "Study of Renal Toxicity in Wistar Rats Following the Action of Amphotericin B Solution Prepared under Extreme pH Conditions," Food and Nutrition Sciences, Vol. 2 No. 7, 2011, pp. 731-735. doi: 10.4236/fns.2011.27100.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. Sanglard and F. C. Odds, “Resistance of Candida Species to Antifungal Agents: Molecular Mechanisms and Clinical Consequences,” Lancet Infectious Disease, Vol. 2, No. 2, 2002, pp. 73-85. doi:10.1016/S1473-3099(02)00181-0
[2] M. M. Canuto and F. G. Rodero, “Antifungal Drug Resistance to Azoles and Polyenes,” Lancet Infectious Disease, Vol. 2, No. 9, 2002, pp. 550-63.
[3] D. A. Said, E. Anaissie, O. Uzun, H. Pinzkowzki and S. Vartivarian, “The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species,” Clinical Infectious Disease, Vol. 24, No. 6, 1997, pp. 1122-1128. doi:10.1086/513663
[4] A. H. Groll and J. C. Gea-Banacloche, “Clinical Pharmacology of Antifungal Compounds,” Infectious Disease Clinics Of North America, Vol. 17, No. 1, 2003, pp. 159-191.
[5] A. Kettani, Z. H. Belkhadir, A. Mosadik, A. Faroudy, A. Ababou, A. Lazreq and A. Sbihi, “Traitement Antifongique des Candidoses Systémiques en réAnimation,” Journal de Mycologie Médicale, Vol. 16, No. 1, 2006, pp. 16-25.
[6] J. P. Adler-Moore, J. A. Olson and R. T. Proffitt, “Alternative Dosing Regimens of Liposomal Amphotericin B (AmBisome) Effective in Treating Murine Systemic Candidiasis,” Journal of Antimicrobial Chemotherapy, Vol. 54, No. 6, 2004, pp. 1096-1102. doi:10.1093/jac/dkh460
[7] B. Blanchet, E. Huet, A. Astier and A. Hulin, “Suivie Thérapeutique des Médicaments Antifongiques. Pharmacocinétique des Médicaments Infectieux,” Revue Fran?aise des Laboratoires, Vol. 2004, No. 365, 2004, pp. 39-47.
[8] M. Mariné, R. Espada, J. Torrado, F. J. Pastor and J. Guarro, “Efficacy of a New Formulation of Amphotericin B in a Murine Model of Disseminated Infection by Candida Glabrata,” Journal of Antimicrobial Chemotherapy, Vol. 61, No. 4, 2008, pp. 1-4.
[9] F. Gaboriau, M. Cheron, C. Petit and J. Bolard, “Heat-In- duced Superaggregation of Amphotericin B Reduces Its in Vitro Toxicity: A New Way to Improve Its Therapeutic Index,” Antimicrobial Agents and Chemotherapy, Vol. 41, No. 11, 1997, pp. 2345-2351.
[10] C. Petit, M. Cheron, V. Joly, J. M. Rodrigues, J. Bolard and F. Gaboriau, “In-Vivo Therapeutic Efficacy in Experimental Murine Mycoses of a New Formulation of Deoxycholate-Amphotericin B Obtained by Mild Heating,” Journal of Antimicrobial Chemotherapy, Vol. 42, No. 6, 1998, pp. 779-785. doi:10.1093/jac/42.6.779
[11] R. Espada, S. Valdespina, M. A. Dea, G. Molero, M. P. Ballesteros, F. Bola and J. J. Torrado, “In Vivo Distribution and Therapeutic Efficacy of a Novel Amphotericin B Poly-Aggregated Formulation,” Journal of Antimicrobial Chemotherapy, Vol. 61, No. 5, 2008, pp. 1-7.
[12] L. Belkherroubi-Sari, Z. Boucherit, M. Chéron, K. Bou- cherit, M. Benyoucef and S. Belbraouet, “Modulation of the Polyene Antibiotic Amphotericin B Selective Toxicity by pH Change of the Stock Solutions,” African Journal of Microbiology Research, Vol. 2, 2008, pp. 242-246
[13] M. Kleinberg, “What Is the Current and Future Status of Conventional Amphotericin B?” International Journal of Antimicrobial Agents, Vol. 27, No. 1, pp. 12-16. doi:10.1016/j.ijantimicag.2006.03.013

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.